Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. Peters BS, et al. Among authors: tarragona t. Vaccine. 2007 Mar 1;25(11):2120-7. doi: 10.1016/j.vaccine.2006.11.016. Epub 2006 Nov 27. Vaccine. 2007. PMID: 17250931 Clinical Trial.
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Waruingi W, Odada J, Oyaro M, Indangasi J, Ndinya-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmour J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu P. Jaoko W, et al. Among authors: tarragona t. Vaccine. 2008 May 23;26(22):2788-95. doi: 10.1016/j.vaccine.2008.02.071. Epub 2008 Mar 31. Vaccine. 2008. PMID: 18440674 Clinical Trial.
A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.
Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, Lehrman J, Stevens G, Gilmour J, Tarragona T, Hayes P, Lowenbein S, Kizito E, Fast P, Heald AE, Schmidt C. Vardas E, et al. Among authors: tarragona t. AIDS Res Hum Retroviruses. 2010 Aug;26(8):933-42. doi: 10.1089/aid.2009.0242. AIDS Res Hum Retroviruses. 2010. PMID: 20666584 Clinical Trial.
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour J. Boaz MJ, et al. Among authors: tarragona t. Clin Vaccine Immunol. 2009 Feb;16(2):147-55. doi: 10.1128/CVI.00326-08. Epub 2008 Dec 17. Clin Vaccine Immunol. 2009. PMID: 19091991 Free PMC article.